1147-D Preclinical characterization of a novel claudin 18.2 targeting-ISAC with robust potency and acceptable safety profile

Bibliographic Details
Main Authors:	Matthew Zhou, William Mallet, Romas Kudirka, Han K Kim, Justin Monnier, Chi-Ling Fu, Jennifer E Melrose, Hung Dao, Paul D Ponath, Katelynn A McEachin, David T Omstead, Cindy Kreder, Stefan Chun, Ying Yueh Lee, Rachel Grgich, Tracey J Lin, Joshua A Walker, Karla A Henning, Shelley E Ackerman, Diane Carrera, Steven J Chapin, Dowdy Jackson, Changshou Gao, Michael N Alonso
Format:	Article
Language:	English
Published:	BMJ Publishing Group 2023-11-01
Series:	Journal for ImmunoTherapy of Cancer

Similar Items

821 The combination of a trastuzumab ISAC and pertuzumab augments anti-tumor efficacy in multiple HER2+ tumor models relative to trastuzumab plus pertuzumab
by: Edith A Perez, et al.
Published: (2023-11-01)

784 BDC-2034: discovery of a CEA-targeting immune-stimulating antibody conjugate (ISAC) for solid tumors
by: Marcin Kowanetz, et al.
Published: (2021-11-01)

Claudin18.2 in Advanced Gastric Cancer
by: Rin Inamoto, et al.
Published: (2023-12-01)

Zolbetuximab for Claudin18.2-positive gastric or gastroesophageal junction cancer
by: Yohei Kubota, et al.
Published: (2024-01-01)

Dawn of Targeted Therapy Using Claudin18.2 for Gastric Cancer
by: LI Hao, et al.
Published: (2023-10-01)

Preclinical characterization of an mRNA-encoded anti-Claudin 18.2 antibody
by: Hayat Bähr-Mahmud, et al.
Published: (2023-12-01)

Antigen-Specific T Cell Immunotherapy Targeting Claudin18.2 in Gastric Cancer
by: Bo Xu, et al.
Published: (2022-06-01)

Claudin18.2 is a novel molecular biomarker for tumor-targeted immunotherapy
by: Weijie Cao, et al.
Published: (2022-05-01)

The SPICE Detector at ISAC
by: Garnsworthy A.B., et al.
Published: (2013-12-01)

659 Repeated dosing of anti-Claudin 18.2 CAR-T in metastatic gastrointestinal cancer
by: Dan Zhao, et al.
Published: (2023-11-01)

Dark horse target Claudin18.2 opens new battlefield for pancreatic cancer
by: Qian Xu, et al.
Published: (2024-03-01)

Anti-claudin 18.2 antibody as new targeted therapy for advanced gastric cancer
by: Prabhsimranjot Singh, et al.
Published: (2017-05-01)

Metastatic gastric cancer target lesion complete response with Claudin18.2-CAR T cells
by: Gregory A Daniels, et al.
Published: (2024-02-01)

ISAC News and Updates
Published: (2021-03-01)

ISAC News and Updates
Published: (2021-06-01)

IM-OFDM ISAC Outperforms OFDM ISAC by Combining Multiple Sensing Observations
by: Hugo Hawkins, et al.
Published: (2024-01-01)

Claudin 18.2 as a New Biomarker in Gastric Cancer—What Should We Know?
by: Maria Cecília Mathias-Machado, et al.
Published: (2024-02-01)

CT041 CAR T cell therapy for Claudin18.2-positive metastatic pancreatic cancer
by: Changsong Qi, et al.
Published: (2023-09-01)

Clinicopathologic features and prognostic value of claudin 18.2 overexpression in patients with resectable gastric cancer
by: Hyung-Don Kim, et al.
Published: (2023-11-01)

Divine Vengeance and Human Justice in The Wendish Crusade of 1147
by: Mihai Dragnea
Published: (2017-03-01)

283 Preclinical development and characterization of allogeneic CAR T cells targeting Claudin18.2-positive tumors
by: Zhe Li, et al.
Published: (2023-11-01)

Development of a Humanized VHH Based Recombinant Antibody Targeting Claudin 18.2 Positive Cancers
by: Weixiang Zhong, et al.
Published: (2022-06-01)

Claudin-18.2 mediated interaction of gastric Cancer cells and Cancer-associated fibroblasts drives tumor progression
by: Shengde Liu, et al.
Published: (2024-01-01)

Disruption of Claudin-1 Expression by miRNA-182 Alters the Susceptibility to Viral Infectivity in HCV Cell Models
by: Sarah E. Riad, et al.
Published: (2018-03-01)

ISACS, an integrated surveillance and control system
by: Jon Kvalem, et al.
Published: (1993-04-01)

Claudin18.2 bispecific T cell engager armed oncolytic virus enhances antitumor effects against pancreatic cancer
by: Shiyu Liu, et al.
Published: (2023-09-01)

Development and comparison of 68Ga/18F/64Cu-labeled nanobody tracers probing Claudin18.2
by: Weijun Wei, et al.
Published: (2022-12-01)

Identifying hypothetical genetic influences on complex disease phenotypes
by: Keller Benjamin J, et al.
Published: (2009-02-01)

Multistatic sensing for target localization in ISAC systems
by: Zhuge, Shun
Published: (2024)

1147-G ERV-derived peptides as novel immunotherapeutic targets in ovarian cancer
by: Ines Mota, et al.
Published: (2023-11-01)

Complete remission of advanced pancreatic cancer induced by claudin18.2-targeted CAR-T cell therapy: a case report
by: Guocheng Zhong, et al.
Published: (2024-02-01)

IL-15 armoring enhances the antitumor efficacy of claudin 18.2-targeting CAR-T cells in syngeneic mouse tumor models
by: Hongtai Shi, et al.
Published: (2023-07-01)

SPectrometer for Internal Conversion Electrons (SPICE) at TRIUMF-ISAC
by: Smallcombe J., et al.
Published: (2016-01-01)

First outcomes from the CNR-ISAC monthly forecasting system
by: D. Mastrangelo, et al.
Published: (2012-04-01)

Hf-182-W-182 chronometry for Renazzo and Bencubbinites
by: Lee, D, et al.
Published: (2002)

FAP-targeted CAR-T suppresses MDSCs recruitment to improve the antitumor efficacy of claudin18.2-targeted CAR-T against pancreatic cancer
by: Yifan Liu, et al.
Published: (2023-04-01)

A Replay Attack Against ISAC Based on OFDM
by: Georgios Chrysanidis, et al.
Published: (2024-01-01)

EE-ISAC—Practical Cybersecurity Solution for the Energy Sector
by: Tania Wallis, et al.
Published: (2022-03-01)

ISAC system assisted by RIS with sparse active elements
by: Mirza Asif Haider, et al.
Published: (2023-02-01)

Accelerated 2D Classification With ISAC Using GPUs
by: Fabian Schöenfeld, et al.
Published: (2022-07-01)